Sanofi has decided to stop the development of its immune drug partnered with Nurix. This decision has led to a sell-off in Nurix shares and has prompted analysts to debate the future prospects of drugs aimed at degrading the challenging protein known as STAT6. The halt in development may raise concerns among investors regarding the viability of similar therapeutic approaches targeting difficult proteins.
Source: biopharmadive.com · Image: New Orleans Pharmacy Museum – 42 by Jeremy Thompson, CC BY 2.0, via Wikimedia Commons
Planning your supply chain?
The API & FDF Intelligence database shows where manufacturers are located, which certificates they hold, and which markets are overheated.
With direct contacts for every supplier and holder, you can move from weeks of outreach to decisions made in hours.
Use the database as your supply chain compass →
Use the database as your supply chain compass →
